A late relapse thymoma and pure red cell aplasia case with an over 5 years of clinical response under everolimus.
| Autor: | Köksoy EB; Department of Medical Oncology, Ankara University, School of Medicine, Ankara, Turkey., Akbulut H |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Anti-cancer drugs [Anticancer Drugs] 2023 Nov 01; Vol. 34 (10), pp. 1193-1195. Date of Electronic Publication: 2023 Oct 11. |
| DOI: | 10.1097/CAD.0000000000001504 |
| Abstrakt: | Although several agents showed some clinical activity in patients with recurrent thymoma, there is no standard treatment option. Here, we report a late relapse thymoma and pure red cell aplasia case, responsive to everolimus with over 5 years of clinical benefit following multiple lines of treatment. Everolimus controlled the rapidly progressive disease in our patient without significant toxicity. (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|